Business Context and Reporting Period
Company: OrthoPediatrics Corp. (Ticker: KIDS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2026
Event: Entry into a material definitive agreement regarding debt financing.
Key Financial Metrics and Debt Structure
This filing details a new credit facility amendment rather than reporting period-end financial results (revenue, profit, or cash flow). Key debt metrics include:
- New Facility: Delayed draw term loan facility with an aggregate principal amount not to exceed $20.0 million.
- Draw Terms: Available until June 30, 2027, in minimum $10.0 million increments.
- Interest Rate: SOFR Interest Rate (floor of 3.25%) plus 6.50%.
- Payment Structure: Interest-only until maturity on August 5, 2029. Includes an option for a 1.00% per annum payment-in-kind (PIK) interest payment.
- Fees: 1.00% upfront fee; 0.05% per annum delayed draw ticking fee; standard exit and prepayment fees.
- Current Draw Status: The Company is not required to draw on the facility immediately upon amendment.
Material Changes Versus Prior Period
The filing represents an amendment to the Term Loan Agreement dated August 5, 2024. The material change is the establishment of incremental committed financing capacity ($20.0 million) via a delayed draw structure. This provides flexibility to access capital only as needed, differing from the previous agreement which did not include this specific delayed draw facility.
Management Commentary, Risks, and Outlook
Management Commentary: The Company views the amendment as an efficient and flexible source of capital that supports disciplined liquidity management and capital deployment while preserving near-term cash flow.
Risks and Contingencies:
- Access to funds is subject to certain conditions set forth in the Amendment.
- The facility is subject to financial covenants.
- Interest rates are variable based on SOFR, subject to a 3.25% floor.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the specific financial covenants required to draw on the $20.0 million facility.
- Review the full text of the First Amendment (Exhibit 10.1) for omitted disclosure schedules regarding fees and conditions.
- Monitor future 10-Q or 10-K filings to determine if and when the Company elects to draw on the delayed draw facility.
- Assess the impact of the 1.00% upfront fee and ticking fees on the Company's overall cost of capital.